MHRA Class 2 Medicines Recall: KidNaps Melatonin Oral Solution

MHRA Guidance & Safety

Published February 23rd, 2026

Detected February 23rd, 2026

Summary

The MHRA has issued a Class 2 medicines recall for all batches of KidNaps Melatonin 1mg in 1ml Oral Solution due to out-of-specification stability results. Sterling Pharmaceuticals Ltd and Veriton Pharma Ltd are conducting the recall at the wholesaler and pharmacy level.

View original document View source feed page

What changed

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 2 medicines recall for all batches of KidNaps Melatonin 1mg in 1ml Oral Solution, manufactured by Sterling Pharmaceuticals Ltd and distributed by Veriton Pharma Ltd. The recall is prompted by confirmed out-of-specification results from annual stability testing, specifically concerning product appearance and total impurities. The DMRC reference number for this action is DMRC-38487919.

Healthcare professionals are instructed to stop supplying the affected batches immediately, quarantine all stock, and return it to their supplier. Patients are advised that no action is required from them, as the recall is at the wholesaler and pharmacy level, and they may continue to use the medication. However, any patients with concerns should consult their healthcare professional, and suspected adverse reactions should be reported via the MHRA Yellow Card scheme.

Source document (simplified)

Class 2 Medicines Recall: Sterling Pharmaceuticals Ltd (specials manufacturer MS 32515), KidNaps (Melatonin) 1mg in 1ml Oral Solution, EL(26)A/09

Sterling Pharmaceuticals Ltd and Veriton Pharma Ltd are recalling all batches of KidNaps (Melatonin) 1mg in 1ml Oral Solution due to out of specification stability results.

From: Medicines and Healthcare products Regulatory Agency Published 23 February 2026 Message type: Medicines recall/notification Medical specialty: Dispensing GP practices and Pharmacy Issued: 23 February 2026

DMRC reference number

DMRC-38487919

Marketing Authorisation Holder

Sterling Pharmaceuticals Ltd (specials manufacturer MS 32515)

Medicine Details

KidNaps (Melatonin) 1mg in 1ml Oral Solution

Licence: MS 32515

Active ingredient: melatonin

SNOMED code: N/A

GTIN: 5060191450331

Affected Lot Batch Numbers

| Batch No. | Expiry Date | Pack Size | First Distributed |
| --- | --- | --- | --- |
| 1743 | Mar 2026 | 200ml | 05/11/2024 |
| 1744 | Mar 2026 | 200ml | 12/11/2024 |
| 1787 | Jun 2026 | 200ml | 04/02/2025 |
| 1788 | Jun 2026 | 200ml | 21/02/2025 |
| 1852 | Dec 2026 | 200ml | 22/04/2025 |
| 1853 | Dec 2026 | 200ml | 27/06/2025 |
| 1955 | Jun 2027 | 200ml | 02/09/2025 |
| 1956 | Jun 2027 | 200ml | 05/11/2025 |
| 1992 | Sep 2027 | 200ml | 14/12/2025 |
| 1993 | Sep 2027 | 200ml | 05/02/2026 |

Background

Sterling Pharmaceuticals Ltd (specials manufacturer MS 32515) and Veriton Pharma Ltd are recalling all batches of KidNaps (Melatonin) 1mg in 1ml Oral Solution within expiry due to confirmed out of specification results from annual stability testing relating to product appearance and total impurities.

Advice for Healthcare Professionals:

Stop supplying the above batches immediately. Quarantine all stock and return it to your supplier using your supplier’s approved process.

Advice for Patients:

No action is required by patients, the recall is at the wholesaler and pharmacy level.

The recall is being undertaken out of an abundance of caution, patients using this medication may continue to do so. No adverse reactions have been reported from patients using this product. Patients or carers who have concerns about their medication should speak to their healthcare professional in the first instance.

Patients who experience adverse reactions or have any questions about the medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.

Additional information:

For medical information enquiries on this product, email centralmedicalinformation@veritonpharma.com or telephone +44 (0)1932 690325.

For stock control enquiries, email orders@veritonpharma.com or telephone +44 (0)1932 690325.

Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Yours faithfully

Defective Medicines Report Centre

10 South Colonnade

Canary Wharf

London

E14 4PU

Telephone +44 (0)20 3080 6574

DMRC@mhra.gov.uk